Leo Cancer Care $65M Series D
Analysis based on 7 articles · First reported Jul 08, 2026 · Last updated Jul 08, 2026
The funding and strategic partnership signal strong investor confidence in Leo Cancer Care's upright cancer care technology, potentially accelerating adoption and market share in the radiation therapy and imaging markets. Competitors in the proton therapy and radiotherapy space may face increased pressure to innovate.
Leo Cancer Care, a medical technology company developing upright cancer imaging and treatment systems, announced the close of an oversubscribed $65 million Series D financing round. The round was led by Galaxy Ventures, with new investor Eventide Asset Management joining existing investors. The funding will scale manufacturing, accelerate commercial deployment, and continue clinical and product development across Leo's integrated upright platform spanning proton therapy, photon therapy, and imaging. The company's Marie platform achieved a milestone on June 4, 2026, when Stanford University School of Medicine delivered the world's first compact upright proton therapy treatment to a seven-year-old child with a brain tumor. Leading institutions including Dana-Farber Cancer Institute and McLaren Health Care are adopting the upright platform. Leo also entered a major strategic partnership with an international healthcare giant, details to be announced later.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard